|Type||Buy / Hold / Sell|
|Year End 31st Mar||Unit||2018||2019||2020||2021||2022||2023E||2024E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets medical device products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The Company offers its products across hospital and homecare settings. The Company’s hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include the Company’s continuous positive airway pressure (CPAP) therapy masks, as well as flow generators, interfaces, and data management technologies. The Company operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India, Germany, Austria, Italy, Turkey, China, Hong Kong, Taiwan, Malaysia, Singapore and Australia.
- Scott St. John NEC
- Lewis Gradon CEO
- Lyndal York CFO
- Paul Shearer SVP
- Nicola Talbot VPR
- Marcus Driller VPR
- Winston Fong VPR
- Nicholas Fourie VPR
- Brian Schultz VPR
- Andrew Robert Somervell VPR
- Jonti Rhodes GMG
- Michael Daniell NED (65)
- Philippa Mary Greenwood NID
- Geraldine McBride NID (60)
- Lisa Mcintyre NID
- Neville Mitchell NID (62)
- Donal O'Dwyer NID (68)
- 15 Maurice Paykel Place, East Tamaki, AUCKLAND, 1061
- +64 95740100
- Hayden Brown
As of Today at 24:08 UTC, shares in Fisher & Paykel Healthcare are trading at NZ$24.16. This share price information is delayed by 15 minutes.
Shares in Fisher & Paykel Healthcare last closed at NZ$24.16 and the price had moved by -24.92% over the past 365 days. In terms of relative price strength the Fisher & Paykel Healthcare share price has underperformed the ASX All Ordinaries Index by -24.67% over the past year.
The overall consensus recommendation for Fisher & Paykel Healthcare is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Fisher & Paykel Healthcare dividend yield is 1.66% based on the trailing twelve month period.
Last year, Fisher & Paykel Healthcare paid a total dividend of NZ$0.40, and it currently has a trailing dividend yield of 1.66%.Looking ahead, shares in Fisher & Paykel Healthcare are due to go ex-dividend on 2022-12-08 and the next dividend pay date is 2022-12-21.
Fisher & Paykel Healthcare are due to go ex-dividend on 2022-12-08 and the next dividend pay date is 2022-12-21. The historic dividend yield on Fisher & Paykel Healthcare shares is currently 1.66%.
To buy shares in Fisher & Paykel Healthcare you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NZ$24.16, shares in Fisher & Paykel Healthcare had a market capitalisation of NZ$13.86bn.
Here are the trading details for Fisher & Paykel Healthcare:
- Country of listing: New Zealand
- Exchange: NZC
- Ticker Symbol: FPH
Based on an overall assessment of its quality, value and momentum Fisher & Paykel Healthcare is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Fisher & Paykel Healthcare is NZ$23.12. That is 4.32% below the last closing price of NZ$24.16.
Analysts covering Fisher & Paykel Healthcare currently have a consensus Earnings Per Share (EPS) forecast of NZ$0.37 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fisher & Paykel Healthcare. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +15%.
As of the last closing price of NZ$24.16, shares in Fisher & Paykel Healthcare were trading +12.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Fisher & Paykel Healthcare PE ratio based on its reported earnings over the past 12 months is 52.74. The shares last closed at NZ$24.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Fisher & Paykel Healthcare's management team is headed by:
- Scott St. John - NEC
- Lewis Gradon - CEO
- Lyndal York - CFO
- Paul Shearer - SVP
- Nicola Talbot - VPR
- Marcus Driller - VPR
- Winston Fong - VPR
- Nicholas Fourie - VPR
- Brian Schultz - VPR
- Andrew Robert Somervell - VPR
- Jonti Rhodes - GMG
- Michael Daniell - NED
- Philippa Mary Greenwood - NID
- Geraldine McBride - NID
- Lisa Mcintyre - NID
- Neville Mitchell - NID
- Donal O'Dwyer - NID